Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAmwcqsxCeb1ncYsvxpKIuP_kRnM5oWXoWLShRn3uDFsM#assertion>. }
Showing items 1 to 22 of
22
with 100 items per page.
- subject C0011777 "dexamethasone" assertion.
- object C5203670 "COVID-19" assertion.
- subject C0812732 "azithromycin" assertion.
- subject C0052796 "azithromycin" assertion.
- object C3273539 "management" assertion.
- object C1521721 "supporting" assertion.
- object C1273870 "management" assertion.
- object C0376636 "management" assertion.
- object C0001554 "management" assertion.
- subject C3885145 "sarilumab" assertion.
- subject C1609165 "tocilizumab" assertion.
- subject C0015620 "famotidine" assertion.
- subject C0007561 "ceftriaxone" assertion.
- predicate select?q=TRIPLE_UID:pg3ngnxg-TRIPLE-ABSTRACT-3 "be" assertion.
- object C1552578 "investigation" assertion.
- object C1261322 "investigation" assertion.
- object C0220825 "investigation" assertion.
- triple label "azithromycin , dexamethasone , tocilizumab , sarilumab , famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management" assertion.
- sentence label "Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management." assertion.
- version value "1" assertion.
- assertion wasGeneratedBy "S&T TWOC project version 1" assertion.
- Triple-UID select?q=TRIPLE_UID:pg3ngnxg-TRIPLE-ABSTRACT-3 "pg3ngnxg-TRIPLE-ABSTRACT-3" assertion.